Predictive factors for exacerbation and re-exacerbation in chronic obstructive pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohort.

Urwyler, Pascal; Abu Hussein, Nebal; Bridevaux, Pierre O; Chhajed, Prashant N; Geiser, Thomas; Grendelmeier, Peter; Joos Zellweger, Ladina; Kohler, Malcolm; Maier, Sabrina; Miedinger, David; Tamm, Michael; Thurnheer, Robert; Dieterle, Thomas; Leuppi, Joerg D (2019). Predictive factors for exacerbation and re-exacerbation in chronic obstructive pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohort. Multidisciplinary respiratory medicine, 14(7), p. 7. BioMed Central 10.1186/s40248-019-0168-5

Preview

Text document.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (625kB) | Preview

Background

The Swiss COPD cohort was established in 2006 to collect data in a primary care setting. The objective of this study was to evaluate possible predictive factors for exacerbation and re-exacerbation.

Methods

In order to predict exacerbation until the next visit based on the knowledge of exacerbation since the last visit, a multistate model described by Therneau and Grambsch was performed.

Results

Data of 1,247 patients (60.4% males, 46.6% current smokers) were analyzed, 268 (21.5%) did not fulfill spirometric diagnostic criteria for COPD. Data of 748 patients (63% males, 44.1% current smokers) were available for model analysis. In order to predict exacerbation an extended Cox Model was performed. Mean FEV/FVC-ratio was 53.1% (±11.5), with a majority of patients in COPD GOLD classes 2 or 3. Hospitalization for any reason (HR1.7;  = 0.04) and pronounced dyspnea (HR for mMRC grade four 3.0;  < 0.001) at most recent visit as well as prescription of short-acting bronchodilators (HR1.7;  < 0.001), inhaled (HR1.2;  = 0.005) or systemic corticosteroids (HR1.8;  = 0.015) were significantly associated with exacerbation when having had no exacerbation at most recent visit. Higher FEV/FVC (HR0.9;  = 0.008) and higher FEV values (HR0.9;  = 0.001) were protective. When already having had an exacerbation at the most recent visit, pronounced dyspnea (HR for mMRC grade 4 1.9;  = 0.026) and cerebrovascular insult (HR2.1;  = 0.003) were significantly associated with re-exacerbation. Physical activity (HR0.6;  = 0.031) and treatment with long-acting anticholinergics (HR0.7;  = 0.044) seemed to play a significant protective role. In a best subset model for exacerbation, higher FEV significantly reduced and occurrence of sputum increased the probability of exacerbation. In the same model for re-exacerbation, coronary heart disease increased and hospitalization at most recent visit seemed to reduce the risk for re-exacerbation.

Conclusion

Our data confirmed well-established risk factors for exacerbations whilst analyzing their predictive association with exacerbation and re-exacerbation. This study confirmed the importance of spirometry in primary care, not only for diagnosis but also as a risk evaluation for possible future exacerbations.

Trial registration

Our study got approval by local ethical committee in 2006 (EK Nr. 170/06) and was registered retrospectively on ClinicalTrials.gov (NCT02065921, 19 of February 2014).

Interest & Impact

Downloads

333 since deposited on 08 Aug 2019
20 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item